---
title: Continuous medication reduces motor fluctuations
nct_id: NCT06916507
status: RECRUITING
sponsor: AbbVie
study_type: OBSERVATIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT06916507"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06916507"
last_fetched: "2026-05-10T14:02:50.316Z"
source: "Parkinson's Pathways (curated)"
---
# Continuous medication reduces motor fluctuations

**Goal (in five words):** Continuous medication reduces motor fluctuations

**Official Title:** German Real-World Evidence Study on the Effectiveness of Foslevodopa/Foscarbidopa at Initial Stages of Advanced Parkinson's Disease: Motor Symptoms, Quality of Life, Psychosocial Functioning and Work Ability

**Trial ID:** [NCT06916507](https://clinicaltrials.gov/study/NCT06916507)

## Key Facts

- **Status:** RECRUITING
- **Study Type:** OBSERVATIONAL
- **Sponsor:** AbbVie
- **Target Enrollment:** 125 participants
- **Start Date:** 2025-05-06
- **Completion Date:** 2027-09
- **Conditions:** Parkinson's Disease

## Summary For Families

The goal is to see whether starting foslevodopa/foscarbidopa early in the advanced phase can improve motor symptoms, quality of life, psychosocial functioning and ability to work in routine clinical care. Foslevodopa/foscarbidopa is a prodrug that converts to levodopa and carbidopa and is given as a continuous formulation to keep steadier levodopa levels, which can reduce wearing-off and motor fluctuations that happen with intermittent oral levodopa and may alter oral dosing needs. The study is enrolling adults 18 to 64 with levodopa-responsive idiopathic Parkinson's, motor fluctuations for three years or less, Hoehn and Yahr stage under 3 on medication, MMSE 24 or higher, no prior device-aided therapy, and a clinician who has already decided to start LDp/CDp.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 64 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* Participants with a diagnosis of levodopa-responsive idiopathic Parkinson's disease
* Eligibility for foscarbidopa/foslevodopa (LDp/CDp) therapy in accordance with the approved local label
* Participant must be an adult male or female, 18-64 years of age
* Time since beginning of motor fluctuations ≤ 3 years
* The Hoehn and Yahr (H\&Y) stage \< 3 in the on-medication condition
* Decision to treat with LDp/CDp made by the clinician prior to any decision to approach the participant to participate in this study

Exclusion Criteria:

* Previous Exposure to any device-aided therapy (DAT).
* Any condition included in the contraindications section of the approved local LDp/CDp label.
* Participants with Mini mental state examination (MMSE) score \< 24
```

## Locations (13)

- Universitaetsklinikum Heidelberg /ID# 274164, Heidelberg, Baden-Wurttemberg, Germany _(49.4077, 8.6908)_
- Universitaetsklinikum Tuebingen /ID# 275828, Tübingen, Baden-Wurttemberg, Germany _(48.5227, 9.0522)_
- Praxis Prof. Kassubek/Prof. Riecker /ID# 274165, Ulm, Baden-Wurttemberg, Germany _(48.3984, 9.9916)_
- Parkinson-Klinik Ortenau GmbH&Co KG /ID# 274161, Wolfach, Baden-Wurttemberg, Germany _(48.2932, 8.2158)_
- Klinikum der Universitaet Muenchen Grosshadern /ID# 274168, Munich, Bavaria, Germany _(48.1374, 11.5755)_
- Klinikum Ernst von Bergmann /ID# 274176, Potsdam, Brandenburg, Germany _(52.3989, 13.0657)_
- Universitaetskliniken Giessen und Marburg /ID# 274224, Marburg, Hesse, Germany _(50.8090, 8.7707)_
- Knappschaftskrankenhaus Bottrop /ID# 274284, Bottrop, North Rhine-Westphalia, Germany _(51.5239, 6.9285)_
- Cellitinnen-NTC Neurologisches Therapiecentrum /ID# 277865, Cologne, North Rhine-Westphalia, Germany _(50.9333, 6.9500)_
- Universitaetsklinikum Carl Gustav Carus Dresden /ID# 274167, Dresden, Saxony, Germany _(51.0509, 13.7383)_
- Krankenhaus Martha-Maria Halle-Dölau /ID# 274174, Halle, Saxony-Anhalt, Germany _(51.4816, 11.9795)_
- Praxis MD Oehlwein /ID# 274222, Gera, Thuringia, Germany _(50.8803, 12.0819)_
- Asklepios Fachklinikum Stadtroda /ID# 274162, Stadtroda, Thuringia, Germany _(50.8568, 11.7268)_

## Central Contacts

- Medical Information Germany — (CONTACT) — 49 611 1720 1520 — medinfo.germany@abbvie.com

---

*Canonical: https://parkinsonspathways.com/trial/NCT06916507*  
*HTML version: https://parkinsonspathways.com/trial/NCT06916507*  
*Source data: https://clinicaltrials.gov/study/NCT06916507*